A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Martin, David A ^a   Churchill, Melvin ^b   Flores Suarez, Luis F ^c   Cardiel, Mario H ^d   Wallace, Daniel ^e   Martin, Richard ^f   Phillips, Kristine ^g   Kaine, Jeffrey L ^h   Dong, Hua ^i,j   Salinger, David ^a   Stevens, Erin ^a   Russell, Chris B ^a   Chung, James B ⁱ  

^a AMGEN INC   (United States)

^b Arthritis Center of Nebraska   (United States)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d Clinical Research Center of Morelia   (Mexico)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h Sarasota Arthritis Center   (United States)

ⁱ AMGEN INC   (United States)

^j GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; INTERLEUKIN 17 RECEPTOR; PLACEBO; ANTIRHEUMATIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CANADA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HERPES ZOSTER; HUMAN; LEUKOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MEXICO; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NEUTROPHIL COUNT; NONCARDIAC CHEST PAIN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; AGED; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG RESISTANCE; HEADACHE; IMMUNOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; COUGH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HEADACHE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-17; TREATMENT OUTCOME;

EID: 84886226230     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4347     Document Type: Article

References (21)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
2. Daikh DI, St Clair EW. Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road. Arthritis Care Res 2012, 64:648-651.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639. 10.1002/acr.21641, 22473917.
4. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011, 23:613-619. 10.1016/j.coi.2011.07.006, 3190066, 21852080.
5. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898. 10.1056/NEJMra0707449, 19710487.
6. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776. 10.1038/nrd3794, 23023676.
7. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189. 10.1056/NEJMoa1109017, 22455412.
8. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352. 10.1172/JCI5703, 408356, 10225978.
9. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-R795. 10.1186/ar1733, 1175027, 15987480.
10. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
11. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008, 58:875-887. 10.1002/art.23291, 2675006, 18311821.
12. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
13. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939. 10.1002/art.27334, 20131262.
14. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F, Psoriasis Study Group Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72. 10.1126/scitranslmed.3001107, 20926833, Psoriasis Study Group.
15. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502. 10.1002/art.1780350502, 1575785.
16. Martin D, Kerkof K, Chen G, Rees W, Leshinsky N, Kotzin B, Rand H, Williams G, Stevens E, Russell C. Blood-based biomarkers in a healthy volunteer study of AMG 827 enable assessment of target coverage and functional blockade of the human IL-17 receptor [abstract]. Federation of Clinical Immunology Societies 12th Annual Meeting 2012, Vancouver, BC, Canada.
17. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP, Secukinumab in Crohn's Disease Study Group Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. 10.1136/gutjnl-2011-301668, 22595313, Secukinumab in Crohn's Disease Study Group.
18. Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-2469. 10.1038/jid.2012.163, 22622425.
19. Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate [abstract 831]. Arthritis Rheum 2012, 64:S362. doi:10.1002/art.38564.
20. Genovese MC, Greenwald MW, Cho CS, Berman A, Jin L, Cameron G, Wang L, Xie L, Braun D, Subhashis B, Warner L. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naive to biologic therapy or inadequate responders to tumor necrosis factor α inhibitors [abstract]. Arthritis Rheum 2011, 63:2591.
21. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013, 72:863-869. 10.1136/annrheumdis-2012-201601, 22730366.